Argenica Therapeutics Ltd · ASX:AGN
Argenica Therapeutics — Investor Presentation (June 2021)
25 slides from Argenica Therapeutics's investor presentation, June 2021
Slide 1: Argenica Therapeutics June 2021
ARGENICA THERAPEUTICS JUNE 2021 1 www.argenica.com.au
Slide 2: Disclaimer
This presentation has been prepared by Argenica Therapeutics Limited and its related entities (the “Company”) and is not an offer document. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You shoul
Slide 3: Presentation overview
ARGENICA THERAPEUTICS Overview of how Argenica’s leading Our current phase of An introduction to Argenica, the capital therapeutic candidate could potentially development, clinical trial structure of the business, it’s IP position protect brain tissue against damage roadmap and the team executing an
Slide 4: Developing novel therapeutics to reduce damage to brain cells after stroke
ARGENICA THERAPEUTICS Developing novel therapeutics to reduce damage to brain cells during and after stroke for improved patient outcomes. 4 www.argenica.com.au
Slide 5: Argenica neuroprotective therapeutics overview
Argenica is developing “best in class” novel neuroprotective therapeutics that ARGENICA THERAPEUTICS provide protection for brain cells that would otherwise potentially be irreparably damaged by stroke, and other types of brain injury. The Argenica project has been in development for over 6 years, w
Slide 6: Capital structure
Total Shares on issue 73,172,250 Other Shareholders ARGENICA THERAPEUTICS Inventors and Shares subject to escrow for 12 months 1 4,650,000 SHAREHOLDERS 6 Research Team Shares subject to escrow for 24 months 2 22,625,752 4.7% 5.4% 3.7% 19% 21% 47% Options on issue (escrow for 24 months) 2 & 3 8,300,0
Slide 7: Investment highlights
3# EXPERIENCED BOARD & MANAGEMENT An exceptional team with expertise in drug development ARGENICA THERAPEUTICS commercialisation and capital markets. 1# SOLVING AN UNMET CLINICAL NEED 2# Currently there are no marketed POSITIVE PRE- 4# safe, early intervention therapeutics capable of protecting the
Slide 8: Global burden of stroke
Number of stroke victims each year globally 1 15m 14m 13m 12m 15 MILLION PEOPLE suffer from a stroke globally each year 11m The estimated cost to treat stroke is expected to be $183 Billion by 2030 2 ARGENICA THERAPEUTICS 10m 9m Significant global research efforts are currently underway to find 8m 5
Slide 9: IP assigned to Argenica
IP ASSIGNED TO ARGENICA Core Intellectual Property (IP) is assigned from The University of Western Australia (UWA). Developed in partnership with world renowned Perron Institute for Neurological and Translational Science. ARGENICA THERAPEUTICS GRANTED PATENTS The core patent has been granted in the
Slide 10: Protecting the brain is crucial after stroke
ARGENICA THERAPEUTICS The damage left by stroke can cause lasting damage to brain tissue, long term disability, and even death. This makes protecting the brain crucial. 10 www.argenica.com.au
Slide 11: Stroke damage and unmet need
LEADING CAUSE OF DEATH TIME CRITICAL Stroke is one of the leading causes of Timely diagnosis and treatment is critical mortality and disability worldwide, and after a stroke as the brain ages approximately ARGENICA THERAPEUTICS there are substantial economic costs 3.6 years every hour that appropria
Slide 12: ARG-007 neuroprotective peptide
Reduces ischemia and preserves still viable Safe, regardless of the underlying tissue, immediately protects neurons from cause of stroke, with the potential ARGENICA THERAPEUTICS glucose stress and oxygen deprivation. to extend the treatment window for stroke patients due to preservation of brain ce
Slide 13: Current stroke treatment pathway
Rapidly increasing level of Long term cell damage impacts neural cell death and damage patient outcomes and recovery ARGENICA THERAPEUTICS IN-FIELD TREATMENT REHAB HOSPITAL TRIAGE PLAN Patient in ambulance and 1-4 weeks acute arrives at emergency Diagnose type of stroke Current therapeutic treatment
Slide 14: Argenica treatment pathway
Reduction in Reduction in neural cell death patient recovery and damage time ARGENICA THERAPEUTICS IN-FIELD TREATMENT REHAB HOSPITAL TRIAGE PLAN Patient in ambulance and 1-4 weeks acute arrives at emergency Diagnose type of stroke Current therapeutic treatment hospitalisation1 followed by intensive
Slide 15: Reduction of brain tissue death after stroke
Percentage reduction of brain tissue death after stroke 24 Hours after stroke 28 Days after stroke 100% INDUCED INDUCED 90% STROKE STROKE Reduction in brain cell death 80% can make a significant ARGENICA THERAPEUTICS difference to patients’ 70% outcome. It could mean the difference of walking, talki
Slide 16: Hemorrhagic stroke model safety
Hemorrhagic Stroke Model 30 25 Haematoma volume (uL) ARGENICA THERAPEUTICS 20 ARG-007 does not exacerbate bleeding 15 in hemorrhagic stroke model. Therefore, the peptide is likely to be safe to 10 administer in the field by first responders. This would allow for the protection of brains cells 5 ARG-
Slide 17: Lead candidate ARG-007
ARGENICA THERAPEUTICS Our lead neuroprotective peptide candidate, ARG-007 has been successfully demonstrated to improve outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicity before commencing Phase 1 clinical trials in humans. 17 www.argenica.com.
Slide 18: Drug development pathway
ARGENICA THERAPEUTICS BASIC RESEARCH PRE-CLINICAL STUDIES PHASE I PHASE II PHASE III REVIEW, Discovery and origination Confirmation of safety, Confirmation of Confirmation of efficacy REGULATORY New compound efficacy, of new compounds that such as side effects, in effective safe dosage and safety in
Slide 19: Clinical development timeline
Q2 Q3 Q4 Q1 Q2 Q3 Q4 2021 2021 2021 2022 2022 2022 2022 Contra-indication Assessment ARGENICA THERAPEUTICS GMP Manufacturing Formulation & Stability Pharmacokinetics Safety & Toxicology Phase 1 Clinical Trial Funded pre-IPO raise To be funded from IPO Key progress milestones 19 Indicative schedule o
Slide 20: Protective effect in traumatic brain injury
Significant protective effect in other brain injury models 4 Axonal injury grade (0-4) 3 ARGENICA THERAPEUTICS Traumatic brain injury (TBI) usually results from a violent blow or jolt to the head or body. Preclinical studies show that ARG-007 reduces 2 neuronal injury after TBI. Neuroprotective phar
Slide 21: Hypoxic ischemic encephalopathy
ARGENICA THERAPEUTICS Hypoxic ischemic encephalopathy (HIE) is a type of brain dysfunction that occurs when the brain doesn't receive enough oxygen or blood flow for a period of time. HIE may develop during pregnancy, labour and delivery, or in the postnatal period. HIE is the leading cause of morta
Slide 22: Board and management
Geoff Pocock Dr Liz Dallimore Non-Executive Chairman CEO • 20 years’ experience in commercialisation of emerging technologies • Over 20 years' experience in R&D, technology commercialisation and and capital markets management consulting, including at KPMG, EY and PWC • Non-Executive Director, Osteop
Slide 23: Scientific and clinical advisors
Ass. Prof. Bruni Meloni Geoffrey Donnan CSO & Research Lead Member - CAC Head of Stroke Laboratory Research at UWA and the Perron Institute. Professor Professor of Neurology at The University of Melbourne and former Director Meloni has over 25 years experience as a research scientist, the last 20 in
Slide 24: Summary and near-term milestones
ARGENICA THERAPEUTICS Large potential commercial Value enhancing milestones Well structured business expected in the near term with a robust capital opportunity to reduce damage to brain cells during including, safety and position to execute toxicology results and the development pathway and after s
Slide 25: Contact
ARGENICA THERAPEUTICS For further information please contact: Dr Liz Dallimore CEO E: info@argenica.com.au 25 www.argenica.com.au
Argenica Therapeutics — Investor Presentation (June 2021) on 6ix